Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Related ABT
Company News for April 17, 2014 - Corporate Summary
Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free